Gofire Taps Industry Veteran Joe Hodas to Help Lead Plant-based Medicine Healthcare Revolution

Gofire | April 12, 2019

Gofire Taps Industry Veteran Joe Hodas to Help Lead Plant-based Medicine Healthcare Revolution
DENVER--(BUSINESS WIRE)--Apr 12, 2019--Bringing more than two decades of brand experience and management leadership in CPG, healthcare and alternative medicines, industry leader Joe Hodas is joining healthcare technology firm Gofire™ as President and Chief Operating Officer. Hodas’ broad branding background, marketing skills and extensive industry contacts will be utilized as the company expands relationships with new manufacturing partners and healthcare professionals and launches products in multiple domestic and international markets. “The advancement of plant-based medicines has reached a tipping point. Rarely a day goes by that a new market isn’t opening up through legalization or there isn’t new evidence demonstrating the efficacy of alternative medicines,” Hodas said. “In spite of that momentum, a major gap exists between what consumers and healthcare providers need and the tools to ensure the efficacy, safety and knowledge needed to effectively utilize plant-based medicine. I have known the Gofire team for the past several years and am confident they’re at the forefront of bridging that gap and turning alternative products into mainstream medicine. I’m excited and honored to be a part of that process.” As an early leader in the cannabis industry, Hodas served as the Chief Marketing Officer for national edibles manufacturer, Dixie Brands, Inc., where he helped the company (and the state of Colorado) transition to the first adult-use market in the world. While at Dixie, Hodas drove development of several new THC products, as well as two early CBD brands and helped Dixie expand from one state to five. Most recently, Hodas served as COO of General Cannabis Corp. (OTCQX:CANN), where he oversaw the company’s day-to-day operations and was responsible for driving revenue and efficiency across GC’s existing lines of business. Prior to his cannabis industry experience, Hodas was a partner with a Colorado ad agency where he focused on several healthcare and travel and tourism clients.

Spotlight

Much of the excitement around gene editing is fueled by its potential to treat or prevent human diseases. There are thousands of genetic disorders that can be passed on from one generation to the next; many are serious and debilitating. Genes are the biological templates the body uses to make the structural proteins and enzymes needed to build and maintain tissues and organs. They are made up of strands of genetic code, denoted by the letters G, C, T and A. Humans have about 20,000 genes bundled into 23 pairs of chromosomes all coiled up in the nucleus of nearly every cell in the body.

Related News

PHARMACY MARKET

Rx Linc Partners with Scriptera to Enhance Pharmacies Bottomline

Rx Linc | October 08, 2021

Rx Linc, an emerging Business Intelligence pharmacy Switch network, and Scriptera, an organization whose mission is to create data opportunities for their health care partners, announced a strategic partnership that enables pharmacies to monetize their market-level data through a unique revenue sharing program. We are very excited and pleased to bring Scriptera's data platform and industry opportunities to Rx Linc's Switch Network. Rx Linc is focused on delivering data-driven solutions that provide value and opportunity to our pharmacy customers, By partnering with Scriptera, they fit directly into that mission where we now can monetize de-identified pharmacy claims data back to those that are producing the data daily. For too many years, pharmacy has been producing data that provides significant value to the healthcare ecosystem. It's exciting to be able to deliver value in monetizing this data utilization and at a NO cost program. - Josh Cline, Vice President of Rx Linc. Empower your data with a NO-cost program Scriptera is excited to partner with Rx Linc to bring our platform to their network at no cost, The core values of Scriptera and Rx Linc align perfectly as our core mission is to help see pharmacies succeed in such a challenging time. Scriptera unlocks the hidden value that independent pharmacies have been missing out on by empowering their data. - Kevin Laxer, founder of Scriptera. This partnership comes at a critical time in the pharmacy space as Rx Linc strives to deliver more viable revenue streams to pharmacies. Together, Scriptera and Rx Linc are committed to transforming how pharmacies can benefit from providing de-identified healthcare data. About Rx Linc Rx Linc is a Nationwide Switch network delivering data-driven solutions to their pharmacy customers. Since 1998, Rx Linc has been helping a wide range of pharmacies save time and money through data analysis and proactive outreach to minimize claim errors and maximize reimbursements. Rx Linc's data analytics combined with market intelligence improves pharmacy performance by identifying opportunities at every stage of the claims process. About Scriptera Scriptera creates data opportunities for all our partners in order to unlock more precise and faster insights than ever before. We specialize in solutions for pharmacies, wholesalers, manufacturers, and pharmacy companies. Scriptera's team has deep relationships with all these stakeholders to truly understand and identify their unmet needs.

Read More

InDex Pharmaceuticals to present the successful results of the CONDUCT study at two leading medical conferences

Prnewswire | August 24, 2020

We are very pleased that the abstract with the CONDUCT study results has been selected for oral presentation at both the UEGW and the ACG Annual Scientific Meeting", says Peter Zerhouni, CEO of InDex Pharmaceuticals. "These events are great opportunities for us to further reach the international scientific community with the successful results." UEGW is the largest scientific meeting for gastroenterologists in Europe and is this year held virtually October 11-13. The CONDUCT study will be presented on October 12 during the session "IBD: Clinical trials III" which starts at 16:30 CET. The abstract (OP117) is titled "COBITOLIMOD FOR MODERATE-TO-SEVERE LEFT-SIDED ULCERATIVE COLITIS (CONDUCT): A PHASE IIB, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING TRIAL".

Read More

Fixx Pharmaceuticals Wants to Dominate Hemophilia Market With Gene Editing

Prnewswire | August 28, 2020

Fixx Pharmaceuticals Inc. is pleased to announce the launch of its biotechnology business operations in Las Vegas, Nevada and San Francisco, California. The company is focused on developing a cure for Hemophilia through the use of CRISPR gene editing. There are currently 20,000 people in the U.S. who suffer from hemophilia and 400,000 globally. "We are looking to commercialize a product as soon as possible," says Jesse John Francis Clark, founder of Fixx. "We are going to develop a product that is more cost-effective for payers. We're looking to keep it under $2 million per patient," he said, saying that the overall cost of care of hemophilia patients will decrease. "If we are successful in developing a commercialized product, we are looking at upwards of $40 billion in sales from the U.S. market alone. I think our investors will be happy with that," says Clark.

Read More

Spotlight

Much of the excitement around gene editing is fueled by its potential to treat or prevent human diseases. There are thousands of genetic disorders that can be passed on from one generation to the next; many are serious and debilitating. Genes are the biological templates the body uses to make the structural proteins and enzymes needed to build and maintain tissues and organs. They are made up of strands of genetic code, denoted by the letters G, C, T and A. Humans have about 20,000 genes bundled into 23 pairs of chromosomes all coiled up in the nucleus of nearly every cell in the body.